China is the world's largest chemical raw material medicine production and export country. The results of the latest research shows that Sadie think-tank, recently released, "in recent years, influenced by European and American economic weakness, weak export growth, industry profits decline significantly, the development of China's raw material medicine industry is facing the challenge of industrial transformation and upgrading."Industry profits continue to decline in 2012 to a record low of ten yearsThe results of the study show that, during the period of 2003-2012, chemical raw material medicine industry total profits growth fluctuation obviously, total profit accounted for the proportion of the whole industry is showing a declining trend. In 2012, total profits of chemical raw material medicine industry is 24300000000 yuan, although year-on-year growth of 15.9%, but lower than the growth rate of the medicine manufacturing industry 3.9 percentage points, total profit accounted for pharmaceutical manufacturing proportion from 14% in 2003 to 21.1%, the lowest since 2003.Overcapacity prominent in long-term "price increments"2012 1-12 months, the medicine industry of our country chemical raw materials sales output value of 31364000 yuan, a year-on-year growth of 16.5%, the output 2862000 tons, year-on-year growth of 7.5%, accounting for the global production has more than 1/5, vitamin, penicillin and other bulk raw material of the serious oversupply of production capacity is obvious. Due to overcapacity, market competition, frequent price war. In Europe and America and other countries in anti-dumping trade protection in our country, most of chemical raw materials in the long-term "price increments" predicament.The environmental protection pressure increasing pollutant treatment difficulty